Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

RBNZ rate cut lifts sharemarket, high‑yield stocks climb
Markets Market Close

RBNZ rate cut lifts sharemarket, high‑yield stocks climb

The S&P/NZX 50 Index closed up 0.27% or 37.19 points.

ASB, IAG legal payouts prompt differing verdicts
Markets

ASB, IAG legal payouts prompt differing verdicts

ASB flagged the class action as a contingent liability.

Dairy prices fall for fourth straight auction, whole milk powder down 2.3%
Primary Sector

Dairy prices fall for fourth straight auction, whole milk powder down 2.3%

Prices have slipped again in the latest Global Dairy Trade auction, held overnight on Tuesday, with a 1.6% dip across the board.This was the fourth consecutive decline, following a 0.8% slide at the previous auction, a 4.3% decrease before that, and a 0.3% drop on Aug 19.Whole mi...

ANZ vows to fight CCCFA class action despite ASB settlement
Finance

ANZ vows to fight CCCFA class action despite ASB settlement

“ANZ NZ will continue to defend its case. Our position hasn’t changed.”